NYK 011
Alternative Names: NYK-011Latest Information Update: 17 Jun 2024
At a glance
- Originator Nykode Therapeutics
- Class Antineoplastics; Cancer vaccines; DNA vaccines; Immunotherapies
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Colorectal cancer
Most Recent Events
- 11 Jun 2024 Pharmacodynamics data from a preclinical trial in Colorectal cancer released by Nykode Therapeutics
- 09 Feb 2024 Nykode Therapeutics granted platform patent by European Patent Office and U.S. Patent Office has patent protection (Nykode Therapeutics pipeline February 2024)
- 09 Feb 2024 Preclinical trials in Colorectal cancer in Norway (unspecified route) prior to February 2024 (Nykode Therapeutics Pipeline February 2024)